Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

NCT00420355 ↗

Phase 4 Terminated 19 enrolled University of Oklahoma Abbott · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to determine the pharmacokinetics of lopinavir, ritonavir, and atazanavir when lopinavir/ritonavir and atazanavir are used in combination.

Timeline

Start: 2007-04
Primary completion: 2007-10
Completion: 2008-09

Publications

Rathbun CR, Liedtke MD, Blevins SM, Harrison D, Lockhart SM, Salvaggio M, Acosta EP. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir. HIV Clin Trials. 2009 Sep-Oct;10(5):328-36. doi: 10.1310/hct1005-328.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atazanavir	Other / unclassified	300 mg	—
Subject	Lopinavir	Other / unclassified	400 mg	—
Subject	Ritonavir	Other / unclassified	100 mg	—

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Summary

Timeline

Publications

Drugs

Indications